MBX Biosciences, Inc. Common Stock
MBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.80 | 0.27 | -0.05 | 0.76 |
| FCF Yield | -3.67% | -4.75% | -9.21% | -2.62% |
| EV / EBITDA | -17.43 | -15.75 | -8.20 | -30.52 |
| Quality | ||||
| ROIC | -6.16% | -9.92% | -11.26% | -7.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.90 | 0.95 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -20.91% | 20.11% | -40.79% | -9.56% |
| Safety | ||||
| Net Debt / EBITDA | 10.32 | 1.80 | 1.13 | 2.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |